A rare and aggressive type of brain cancer that often becomes fatal a year after its diagnosis in children and young adults now has its first FDA-approved therapy , a once-weekly capsule from Jazz Pharmaceuticals.

Approval of the drug, dordaviprone, covers adults as well as children age 1 and older who have had at least one prior treatment — either surgery or radiation — for the brain cancer called H3 K27M-mutant diffuse midline glioma. Dublin-based Jazz will market its newest oncology product under the brand name Modeyso. The approval announced late Wednesday came ahead of the Aug. 18 target date for a regulatory decision. Jazz said it expects to launch Modeyso in coming weeks.

H3 K27M-mutant diffuse midline glioma is named for the genetic mutation that drives tumor growth in this typ

See Full Page